Document is current
Any future updates will be listed below
-
Authors
Xu, Binghe https://orcid.org/0000-0003-4195-337X
Zhang, Qingyuan
Zhang, Pin
Hu, Xichun
Li, Wei
Tong, Zhongsheng
Sun, Tao
Teng, Yuee
Wu, Xinhong
Ouyang, Quchang
Yan, Xi
Cheng, Jing
Liu, Qiang
Feng, Jifeng
Wang, Xiaojia
Yin, Yongmei
Shi, Yanxia
Pan, Yueyin
Wang, Yongsheng
Xie, Weimin
Yan, Min
Liu, Yunjiang
Yan, Ping
Wu, Fei
Zhu, Xiaoyu
Zou, Jianjun
,
- License Information
-
More Information
Article History
Received: 20 July 2021
Accepted: 28 September 2021
First Online: 4 November 2021
Competing interests
: B.X. reports receiving research grants from Hengrui, advisory fees from Novartis and Roche and fees for serving on a speakers’ bureau from AstraZeneca, Pfizer, Roche and Eisai. Z.T. reports receiving research grants from Hengrui, Novartis, Bio-Thera and Eli Lilly and Company. X.Y. reports receiving research grants from Hengrui. X.Wang reports receiving research grants from Hengrui, Pfizer and Roche. X.Z., F.W., P.Y. and J.Z. were employees of Hengrui at the time of the study. The other authors declare no competing interests.
